Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

Nicholas Willumsen*, Christina Jensen, George Green, Neel I. Nissen, Jaclyn Neely, David M. Nelson, Rasmus S. Pedersen, Peder Frederiksen, Inna M. Chen, Mogens K. Boisen, Astrid Z. Johansen, Daniel H. Madsen, Inge Marie Svane, Allan Lipton, Kim Leitzel, Suhail M. Ali, Janine T. Erler, Daan P. Hurkmans, Ron H.J. Mathijssen, Joachim AertsMohammed Eslam, Jacob George, Claus Christiansen, Mina J. Bissel, Morten A. Karsdal

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

14 Citations (Scopus)
22 Downloads (Pure)

Abstract

Due to activation of fibroblast into cancer-associated fibroblasts, there is often an increased deposition of extracellular matrix and fibrillar collagens, e.g. type III collagen, in the tumor microenvironment (TME) that leads to tumor fibrosis (desmoplasia). Tumor fibrosis is closely associated with treatment response and poor prognosis for patients with solid tumors. To assure that the best possible treatment option is provided for patients, there is medical need for identifying patients with high (or low) fibrotic activity in the TME. Measuring unique collagen fragments such as the pro-peptides released into the bloodstream during fibrillar collagen deposition in the TME can provide a non-invasive measure of the fibrotic activity. Based on data from 8 previously published cohorts, this review provides insight into the prognostic value of quantifying tumor fibrosis by measuring the pro-peptide of type III collagen in serum of a total of 1692 patients with different solid tumor types and discusses the importance of tumor fibrosis for understanding prognosis and for potentially guiding future drug development efforts that aim at overcoming the poor outcome associated with a fibrotic TME.

Original languageEnglish
Article number204
JournalCellular and Molecular Life Sciences
Volume79
Issue number4
Early online date25 Mar 2022
DOIs
Publication statusPublished - Apr 2022

Bibliographical note

Publisher Copyright: © 2022, The Author(s).

Fingerprint

Dive into the research topics of 'Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types'. Together they form a unique fingerprint.

Cite this